We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EYDAP:ATHEXAthens Water Supply and Sewerage Company S.A. Analysis

Data as of 2026-05-22 - not real-time

€10.30

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Athens Water Supply & Sewerage (EYDAP) is trading at €10.30, modestly above its 20‑day SMA of €10.19 and well above the 200‑day SMA of €7.80, indicating a short‑term bullish bias. The RSI sits at 59.8, suggesting the stock is not yet overbought, but the MACD histogram is negative and the MACD signal is flagged “bearish,” hinting at potential downside pressure. Volume is trending lower while the price hovers near the resistance level of €10.70, adding to the technical caution. On the valuation side, the discounted cash‑flow model assigns a fair value of €3.92, implying an upside/downside metric of –11.6% and classifying the stock as **overvalued**.
Fundamentally, the company reports a negative profit margin (‑5.86%) and a ROE of –2.6%, with free cash flow running at –€27.45 M despite a healthy cash balance of €276 M. Dividend yield is modest at 0.68% with a payout ratio of only 7.4%, raising questions about long‑term sustainability given the earnings shortfall. The beta of 0.02 and sector‑specific low risk suggest price stability, yet 30‑day volatility exceeds 30%, reflecting market sensitivity. Overall, the mix of technical weakness, overvaluation, and weak earnings tempers enthusiasm, while the regulated utility backdrop and modest dividend provide a defensive floor.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram and signal
  • Current price above DCF fair value by >€6
  • Decreasing trading volume near resistance

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Regulated utility revenue provides stability
  • Low beta and sector defensiveness
  • Dividend yield present but earnings remain negative

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • Long‑run infrastructure assets and potential modernization projects
  • Continued government backing reduces regulatory uncertainty
  • Valuation gap may narrow if cash flow improves

Key Metrics & Analysis

Financial Health

Revenue Growth-3.90%
Profit Margin-5.86%
ROE-2.61%
ROA-0.05%
Debt/Equity1.37
P/B Ratio1.4
Op. Cash Flow€16.7M
Free Cash Flow€-27453750
Industry P/E21.9

Technical Analysis

TrendBullish
RSI59.8
Support€9.62
Resistance€10.70
MA 20€10.19
MA 50€9.52
MA 200€7.80
MACDBearish
VolumeDecreasing
Fear & Greed Index91.34

Valuation

Fair Value€3.92
Target Price€9.10
Upside/Downside-11.65%
GradeOvervalued
TypeValue
Dividend Yield0.68%

Risk Assessment

Beta0.02
Volatility30.78%
Sector RiskLow
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.